Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

PURPOSE: Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTE...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Johnston, Stephen R.D., Hegg, Roberto, Im, Seock-Ah, Park, In Hae, Burdaeva, Olga, Kurteva, Galina, Press, Michael F., Tjulandin, Sergei, Iwata, Hiroji, Simon, Sergio D., Kenny, Sarah, Sarp, Severine, Izquierdo, Miguel A., Williams, Lisa S., Gradishar, William J.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2018
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444639/
https://ncbi.nlm.nih.gov/pubmed/29244528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.7824
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires